Cargando…

Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges

The reasons for high morbidity and mortality with Corona virus disease (COVID-19) disease remain unanswered with extremes of manifestation and uncertainty of modes of transmission for which biomarkers are urgently needed for early prediction of severity and prompt treatment. We have reviewed publica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Rishabh, Chourasia, Nidhi, Bharti, Vivek K., Singh, Snigdha, Sarkar, Poulami, Agrawal, Amit, Ghosh, Amrita, Pal, Ranabir, Kanwar, Jagat R., Kotnis, Ashwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638655/
https://www.ncbi.nlm.nih.gov/pubmed/36352911
http://dx.doi.org/10.4103/jfmpc.jfmpc_2283_21
_version_ 1784825468951724032
author Mittal, Rishabh
Chourasia, Nidhi
Bharti, Vivek K.
Singh, Snigdha
Sarkar, Poulami
Agrawal, Amit
Ghosh, Amrita
Pal, Ranabir
Kanwar, Jagat R.
Kotnis, Ashwin
author_facet Mittal, Rishabh
Chourasia, Nidhi
Bharti, Vivek K.
Singh, Snigdha
Sarkar, Poulami
Agrawal, Amit
Ghosh, Amrita
Pal, Ranabir
Kanwar, Jagat R.
Kotnis, Ashwin
author_sort Mittal, Rishabh
collection PubMed
description The reasons for high morbidity and mortality with Corona virus disease (COVID-19) disease remain unanswered with extremes of manifestation and uncertainty of modes of transmission for which biomarkers are urgently needed for early prediction of severity and prompt treatment. We have reviewed publications from PubMed (years 2019–2021) analysing the biochemical, immune-inflammatory, nucleic acid, and cellular biomarkers that predict infection, disease progression in COVID-19 with emphasis on organ-specific damage. Our analysis of 65 biomarkers assessing the impact of SCoV-2 infection on five organs (lung, liver, cardiac, kidney, and neural) reported that increased levels of CRP, TNF-α, ferritin, IL-6, D-dimer, Procalcitonin, Fibrinogen to Albumin Ratio (FAR), and decrease platelet count (PC), lymphocyte count, leukocyte count, and CD4(+)/CD8(+) ratio shows promising association in the early diagnosis, prediction of prognosis and severity disease and also correlates with cytokine storm a cardinal feature of COVID-19 progression. In the above scenario, this review has put forth the most promising biomarkers for COVID diagnosis and prognosis based on the reported literature. In recent year’s chemically synthesized antibody-like biomolecules, aptamers were also used in the diagnosis of COVID-19 which could be preferably used for diagnosis over antibodies. Biomarkers including increase in free DNA and Fibrinogen-to-Albumin Ratio, CRP, PCT, and Ferritin along with a consequential decrease of CD3(+) T, CD4(+) T, CD8(+) T, NK cells with corresponding increase in CD4+/CD8+ ratio following SARS CoV-2 infection has been consistently correlated with disease severity. Despite the two waves of COVID-19 pandemic, currently there is no standard clinical practice guideline for evaluating the severity of the devastating pandemic of COVID-19, hence these biomarkers will have immense relevance for the third and subsequent wave of COVID-19 and related pandemic.
format Online
Article
Text
id pubmed-9638655
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-96386552022-11-08 Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges Mittal, Rishabh Chourasia, Nidhi Bharti, Vivek K. Singh, Snigdha Sarkar, Poulami Agrawal, Amit Ghosh, Amrita Pal, Ranabir Kanwar, Jagat R. Kotnis, Ashwin J Family Med Prim Care Review Article The reasons for high morbidity and mortality with Corona virus disease (COVID-19) disease remain unanswered with extremes of manifestation and uncertainty of modes of transmission for which biomarkers are urgently needed for early prediction of severity and prompt treatment. We have reviewed publications from PubMed (years 2019–2021) analysing the biochemical, immune-inflammatory, nucleic acid, and cellular biomarkers that predict infection, disease progression in COVID-19 with emphasis on organ-specific damage. Our analysis of 65 biomarkers assessing the impact of SCoV-2 infection on five organs (lung, liver, cardiac, kidney, and neural) reported that increased levels of CRP, TNF-α, ferritin, IL-6, D-dimer, Procalcitonin, Fibrinogen to Albumin Ratio (FAR), and decrease platelet count (PC), lymphocyte count, leukocyte count, and CD4(+)/CD8(+) ratio shows promising association in the early diagnosis, prediction of prognosis and severity disease and also correlates with cytokine storm a cardinal feature of COVID-19 progression. In the above scenario, this review has put forth the most promising biomarkers for COVID diagnosis and prognosis based on the reported literature. In recent year’s chemically synthesized antibody-like biomolecules, aptamers were also used in the diagnosis of COVID-19 which could be preferably used for diagnosis over antibodies. Biomarkers including increase in free DNA and Fibrinogen-to-Albumin Ratio, CRP, PCT, and Ferritin along with a consequential decrease of CD3(+) T, CD4(+) T, CD8(+) T, NK cells with corresponding increase in CD4+/CD8+ ratio following SARS CoV-2 infection has been consistently correlated with disease severity. Despite the two waves of COVID-19 pandemic, currently there is no standard clinical practice guideline for evaluating the severity of the devastating pandemic of COVID-19, hence these biomarkers will have immense relevance for the third and subsequent wave of COVID-19 and related pandemic. Wolters Kluwer - Medknow 2022-08 2022-08-30 /pmc/articles/PMC9638655/ /pubmed/36352911 http://dx.doi.org/10.4103/jfmpc.jfmpc_2283_21 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Mittal, Rishabh
Chourasia, Nidhi
Bharti, Vivek K.
Singh, Snigdha
Sarkar, Poulami
Agrawal, Amit
Ghosh, Amrita
Pal, Ranabir
Kanwar, Jagat R.
Kotnis, Ashwin
Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges
title Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges
title_full Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges
title_fullStr Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges
title_full_unstemmed Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges
title_short Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges
title_sort blood-based biomarkers for diagnosis, prognosis, and severity prediction of covid-19: opportunities and challenges
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638655/
https://www.ncbi.nlm.nih.gov/pubmed/36352911
http://dx.doi.org/10.4103/jfmpc.jfmpc_2283_21
work_keys_str_mv AT mittalrishabh bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT chourasianidhi bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT bhartivivekk bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT singhsnigdha bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT sarkarpoulami bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT agrawalamit bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT ghoshamrita bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT palranabir bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT kanwarjagatr bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges
AT kotnisashwin bloodbasedbiomarkersfordiagnosisprognosisandseveritypredictionofcovid19opportunitiesandchallenges